UK’s MHRA Grants Marketing Authorisation for Pfizer’s CIBINQO® (abrocitinib) for Adults and Adolescents With Moderate to Severe Atopic Dermatitis
Pfizer has received marketing authorization from the UK MHRA for CIBINQO (abrocitinib), a once-daily oral JAK1 inhibitor. This drug is approved for treating moderate to severe atopic dermatitis in patients aged 12 and older who require systemic therapy. The authorized doses are 100mg and 200mg. This marks the first marketing authorization globally for abrocitinib, following its PIM designation last year. Pfizer aims to collaborate with NICE and the Scottish Medicines Consortium to ensure patient access to this treatment.
- Marketing authorization received for abrocitinib in Great Britain for moderate to severe atopic dermatitis.
- First marketing authorization globally for abrocitinib.
- Dosages approved: 100mg and 200mg.
- Collaboration planned with NICE and Scottish Medicines Consortium for routine patient access.
- None.
-Abrocitinib is a once-daily oral JAK1 inhibitor indicated in
-This is the first marketing authorization globally for abrocitinib-
“We welcome the MHRA’s authorization of abrocitinib to treat people with moderate to severe atopic dermatitis. This is an important development for people in
Last year, abrocitinib received a Promising Innovative Medicine (PIM) designation from the MHRA. In January of this year, abrocitinib was granted a positive scientific opinion for an Early Access to Medicines Scheme (EAMS) from the MHRA for people with severe atopic dermatitis requiring treatment with systemic therapy and who have had inadequate response or have lost response to licensed systemic therapies, or who are ineligible or intolerant of licensed systemic therapies. This enabled healthcare professionals to prescribe the treatment prior to marketing authorization, based on clinical factors for patients with a clear unmet need.
Regulatory applications for abrocitinib have been submitted to countries around the world for review, including
About Atopic Dermatitis
AD is a chronic skin disease characterized by inflammation of the skin and skin barrier defects.i,ii Lesions of AD are characterized by erythema (skin turning red or purple depending on normal skin color), itching, induration (hardening)/papulation (formulation of papules), and oozing/crusting.ii,iii
AD is one of the most common, chronic, relapsing childhood dermatoses, affecting up to
About CIBINQO® (abrocitinib)
CIBINQO (abrocitinib) is an oral small molecule that selectively inhibits Janus kinase (JAK) 1. Inhibition of JAK1 is thought to modulate multiple cytokines involved in pathophysiology of AD, including interleukin IL-4, IL-13, IL-31, IL-22, and thymic stromal lymphopoietin (TSLP).vii
SAFETY INFORMATION
A total of 3,128 patients were treated with CIBINQO in clinical studies in atopic dermatitis. There were 994 patients with at least 48 weeks of exposure. Five placebo‑controlled studies were integrated (703 patients on 100mg once daily, 684 patients on 200mg once daily and 438 patients on placebo) to evaluate the safety of CIBINQO in comparison to placebo for up to 16 weeks.
The most commonly reported adverse reactions occurring in ≥
For further safety information including warnings, precautions and adverse reactions, please refer to the Summary of Product Characteristics.
About
At
Disclosure Notice
The information contained in this release is as of
This release contains forward-looking information about a product candidate, abrocitinib, including an approval by the MHRA and their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and when drug applications may be filed in any other jurisdictions for any potential indication for abrocitinib; whether and when the applications for abrocitinib pending with the
A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended
_______________________________________
i Hanifin JM, Reed ML. A population-based survey of eczema in
ii Bieber T. Atopic dermatitis. Dermatology. 2012;1(3):203-217.
iii Oszukowska M, Michalak I, Gutfreund K, et al. Role of primary and secondary prevention in atopic dermatitis. Postep Derm Alergol. 2015:32(6):409-420.
iv Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(suppl 1):8-16.
v Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nature Reviews Disease Primers. 2018;4(1):1.
vi
vii Silverberg J I, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis. JAMA Dermatology. 2020;156(8): 863-873
PP-ABR-GLB-0162
View source version on businesswire.com: https://www.businesswire.com/news/home/20210909005232/en/
Media Relations:
+1 (212) 733-1538
Steven.Danehy@pfizer.com
Investor Relations:
+1-212-733-0437
Christopher.stevo@pfizer.com
Source:
FAQ
What is CIBINQO (abrocitinib) approved for?
What regulatory body granted Pfizer authorization for CIBINQO?
When was the marketing authorization for CIBINQO granted?
What are the approved dosages for abrocitinib?